Please assess the completion status of the following clinical trial:

Trial Title: Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with osteoarthritis or rheumatoid Arthritis with or at risk of developing cardiovascular disease and who require and eligible for chronic, daily therapy with an NSAID to control arthritis sign and symptoms.~Exclusion Criteria:~* Subjects have had a recent cardiovascular event, unstable cardiovascular conditions, or any major surgery (cardiac or non-cardiac) within 3 months prior to randomization;~* Subjects with medical or laboratory abnormality that would make the subject inappropriate for entry into this trial~* Subjects require treatment with aspirin \> 325 mg /day~* Subjects with known hypersensitivity to celecoxib, ibuprofen, naproxen, aspirin or esomeprazole, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- celecoxib (Type: EXPERIMENTAL): subject receives celecoxib and dummy (placebo) ibuprofen and naproxen
- ibuprofen (Type: ACTIVE_COMPARATOR): subject receives ibuprofen and dummy (placebo) celecoxib and naproxen
- naproxen (Type: ACTIVE_COMPARATOR): subject receives naproxen and dummy (placebo) celecoxib and ibuprofen

Based on this trial design, predict the completion outcome and termination type (if applicable).